,0,1
0,reviewed journal,9.0
1,mdr acinetobacter baumannii,9.0
2,san francisco,9.0
3,application thereto,9.0
4,neonatal sepsis,9.0
5,producing enterobacteriaceae,9.0
6,antibiotic incentives,8.904761904761905
7,producing pathogen,8.68421052631579
8,resistant pathogen,8.588972431077694
9,consolidated statements,8.57852564102564
10,drug application ind,8.555555555555555
11,operating officer,8.5
12,authorize sublicenses related,8.446666666666667
13,inducement exemption,8.434782608695652
14,preferred stock,8.41390728476821
15,therapeutic antibody,8.4
16,bacterial infection,8.395833333333334
17,medical officer,8.375
18,thermo fisher,8.333333333333332
19,representation warranty,8.3125
20,application method,8.305555555555555
21,accounting policy,8.293522267206479
22,marketing authorization application,8.285714285714285
23,owned subsidiary,8.285714285714285
24,balance sheet arrangements,8.269841269841269
25,fide period,8.091503267973856
26,security,8.07857142857143
27,pharmaceutical ingredient,8.074074074074074
28,average number,8.068421052631578
29,balance sheet,8.040674603174605
30,average price,8.027511961722489
31,epic trial,8.0108566252588
32,income tax,8.003663003663004
33,average period,7.959924320605435
34,cash,7.94727668845316
35,patent protection,7.926666666666667
36,iii service,7.893203883495145
37,arm cohort,7.888888888888889
38,lactamase inhibitor,7.868421052631579
39,step decision sequence,7.863636363636363
40,funds,7.852873563218391
41,care trial,7.8342693236714975
42,consulting audit,7.833333333333333
43,consolidated statement,7.811654475381468
44,committed funding,7.768219944082013
45,substantial loss,7.7665903890160175
46,monthly payment,7.75
47,broad enrollment,7.75
48,accounting policy,7.740188933873144
49,net loss,7.734283625730995
50,infectious diseases,7.725563909774436
51,rise,7.72463768115942
52,negative infection,7.7201576576576585
53,substantial expense,7.719333950046252
54,work plans,7.6952380952380945
55,carbapenem antibiotic,7.682539682539683
56,equipment net,7.681652046783626
57,common stock,7.677976548837476
58,positive data,7.656370656370656
59,executive office,7.6410256410256405
60,leasehold improvement equipment,7.62609649122807
61,compensation cost,7.61284437146506
62,epic study,7.612571260898726
63,negative bacteria,7.61003861003861
64,substantial expenditure,7.608695652173912
65,shelf registration statement,7.608128834355828
66,gross proceeds,7.6
67,advance funds,7.598111658456487
68,tax liability,7.577572964669739
69,net proceeds,7.576388888888889
70,fasb issued asu,7.571847507331379
71,united states,7.555555555555555
72,advance payment,7.553571428571429
73,accounting policies,7.535603715170279
74,substantial research,7.51541207008436
75,efficacy data,7.513513513513514
76,clinical trial,7.500935990338164
77,customers,7.485714285714286
78,quot,7.4753086419753085
79,debt instrument,7.464705882352941
80,bacterial infection,7.4596631205673765
81,basis,7.457142857142857
82,ill patient,7.453488372093023
83,lease quot,7.449172576832151
84,annual period,7.439329354930378
85,care study,7.435983959311424
86,financial statement,7.434425743848102
87,additional information,7.431406384814496
88,quot allowance quot,7.430555555555555
89,institution serf,7.430463576158941
90,licensed product,7.428354371201496
91,sublicense revenue payment,7.4264705882352935
92,quot,7.422222222222222
93,cash flow,7.41764705882353
94,worldwide license,7.407407407407407
95,dividend rate,7.400584795321638
96,asset prepaids,7.388888888888888
97,current asset,7.388888888888888
98,accounting policy,7.381757561324125
99,advanced research,7.377304653204566
100,stock option,7.363345487015403
101,market development,7.361105266849007
102,preclinical study,7.359595070422535
103,drug candidate,7.35892634207241
104,qualified research,7.353383084577115
105,net proceeds,7.343055555555555
106,stock plan,7.333660371187965
107,stock plan,7.333660371187965
108,drug application nda,7.333333333333333
109,funding requirements,7.313229018492176
110,line basis,7.311688311688313
111,product candidate,7.3114353026458865
112,common stock,7.307606178467106
113,additional funding,7.307335632139624
114,charitable foundation,7.301044634377968
115,monthly payment,7.293032786885246
116,commercial launch,7.283333333333334
117,term investment,7.283008690440516
118,net cash,7.269035947712419
119,expense,7.268533034714445
120,debt obligation,7.265789473684211
121,cash cash,7.264923747276689
122,financial asset,7.263796909492274
123,pay royalty,7.260714285714286
124,fisher plan,7.253086419753086
125,cash flow,7.241971383147854
126,administrative expenses,7.240847387906211
127,planned operation,7.236714975845411
128,investment revenue recognition,7.236134125011507
129,operating plan,7.2253086419753085
130,additional financing,7.21912568306011
131,bank deposit cash,7.21764705882353
132,unexercised page,7.214285714285715
133,physician market research,7.212838866890039
134,wa,7.210108604845447
135,financial covenant,7.180463576158941
136,stock compensation expense,7.179717996433656
137,stock proceeds,7.177976548837476
138,common stock,7.177976548837475
139,derivative instrument,7.171515918195235
140,day,7.169230769230769
141,related party,7.160952380952381
142,operating asset,7.159722222222222
143,credit risk,7.137931034482758
144,payment cash flows,7.137091503267975
145,net cash,7.136893090569561
146,asprepaid,7.133333333333334
147,material manufacturing process,7.133333333333334
148,comprehensive model,7.131124913733609
149,offering proceeds,7.123287671232877
150,public offering,7.123287671232877
151,period,7.121503267973857
152,gates foundation,7.12127119144663
153,committed funding,7.1206789604754555
154,company,7.119472350343647
155,common stock,7.115476548837476
156,plan options,7.10976798954941
157,access commitments,7.109265734265735
158,note thereto,7.1024043715847
159,future period,7.10202958376333
160,clinical trial,7.094685990338164
161,trial progress,7.094685990338164
162,tax service rent,7.093203883495145
163,important data,7.084942084942085
164,cash proceeds,7.084313725490196
165,outstanding payment,7.080339221196307
166,maturity assets,7.08
167,loan balance,7.072804634488234
168,financial statement,7.0683543152766735
169,additional funding,7.066926424978499
170,debt financing,7.066666666666666
171,grant options,7.065014903129657
172,plazomicin,7.061227365602762
173,ionis,7.053651266766021
174,net headcount,7.049487219130076
175,operating lease,7.048378926038501
176,atm equity program,7.0338495575221245
177,management,7.029761904761905
178,million wa added,7.029156223893066
179,money market,7.014455782312925
180,service fee,7.013685811205988
181,financial statement,7.01141849747129
182,financial statement,6.996925743848102
183,gates foundation,6.995134827810267
184,cash dividend,6.979551820728291
185,material agreement,6.967845659163987
186,external expense,6.9573049645390075
187,trading day,6.956730769230769
188,financial information,6.956077611246661
189,regulatory approval,6.949520624303233
190,stock price comparison,6.947998193859121
191,term liability,6.945759388175312
192,cash dividend,6.936694677871149
193,cash,6.930980392156863
194,drug administration,6.9222222222222225
195,substantial doubt,6.9209911173445535
196,sale proceeds,6.916666666666667
197,improvement allowance,6.914959016393443
198,debt security,6.914935064935065
199,recurring adjustment,6.9125
200,operating expense,6.89985398414685
201,based compensation,6.88540622917356
202,program laboratory supply,6.8825337680484395
203,net loss,6.880950292397661
204,phase study,6.880428403755868
205,patient,6.873778227165487
206,stock option,6.871542208326878
207,market offering,6.866910120212468
208,revenue costs,6.864803921568627
209,stock option,6.863345487015403
210,cash requirement,6.863101604278075
211,product candidate,6.849896841107425
212,net sale,6.840881642512078
213,current asset,6.835555555555555
214,committed funding,6.834886610748681
215,allotment option,6.8326349235586665
216,retrospective basis,6.832053251408091
217,work plans,6.824270353302611
218,market data,6.8196359624931056
219,antidilutive impact,6.810496453900709
220,gates foundation,6.80049197066741
221,plan,6.799504548408057
222,additional funding,6.798018861953288
223,annual return,6.792270531400966
224,foreseeable future,6.790526315789474
225,wa primarily due,6.788975986064452
226,inducement plan,6.774825550187869
227,safety microbiology,6.7727272727272725
228,research,6.769391543472171
229,platform technology,6.763636363636364
230,development manufacturing registration,6.7633161512027495
231,solar capital,6.762800417972832
232,clinical trial,6.7613526570048315
233,development conditions,6.757685520572119
234,marketing approval,6.754047619047618
235,development authority,6.753363384671035
236,company,6.7522208883553425
237,balance sheet date,6.743915343915344
238,regulatory approval,6.729230769230769
239,manufacturing agreement,6.727845659163988
240,cuti,6.7060041407867494
241,substantial research,6.705556997620593
242,commercial validation,6.702564102564103
243,preclinical study,6.692928403755869
244,facility lease,6.68446669447921
245,company,6.68310871398001
246,development manufacturing,6.682433798261573
247,net property,6.681652046783626
248,liability instrument,6.679752967105496
249,financing requirement,6.67719298245614
250,health threat,6.666666666666667
251,expense advance payment,6.664209726443769
252,common share,6.657844559058718
253,approval,6.645554221688675
254,product candidate,6.64476863597922
255,aggregate amount,6.643589743589743
256,related cost,6.639632741985682
257,common stock,6.636501894459595
258,principal amount,6.634615384615385
259,interest method,6.633617494440326
260,research,6.62836590244653
261,derivative liabilities,6.620843471208435
262,development expense,6.612287782408423
263,direct cost,6.604338624338624
264,revenue,6.603691476590637
265,share data,6.599112707874038
266,development funding organization,6.597685520572119
267,note thereto,6.577612704918033
268,revenue research,6.577234625193361
269,niaid contract,6.571453142660573
270,trial,6.564428053830229
271,program,6.561070445877466
272,july niaid extended,6.557142857142857
273,payable approximates,6.552210233205709
274,additional disclosure,6.546694605365874
275,success fee agreement,6.542873041420285
276,cost,6.541838624338624
277,balance sheet,6.539072039072039
278,operation funds,6.534032983508246
279,success fee,6.531549121386733
280,registration statement,6.530003834355828
281,price,6.517616254713029
282,discovery work,6.514115646258504
283,conduct,6.511128542013923
284,nature amount timing,6.5054945054945055
285,security,6.505238095238095
286,term loan,6.50448312148587
287,prevention,6.503529411764705
288,april,6.499574618929458
289,plazomicin,6.493975903614458
290,litigation cost,6.477961812744422
291,stock price liquidity,6.46188708274801
292,market security,6.458767951625095
293,expansion,6.444444444444445
294,mmitt population,6.444444444444445
295,launch plazomicin,6.443975903614458
296,common stock,6.432213836973069
297,payment,6.427220888355342
298,purchase price,6.413328197226503
299,research development,6.397596671677299
300,company,6.385554221688675
301,period management,6.383169934640523
302,ivd assay,6.382864792503346
303,research organization,6.36893864013267
304,limited hovione,6.367647058823529
305,base rent,6.36600790513834
306,share,6.352556558701609
307,key assumption,6.342329545454545
308,modified intent,6.324116743471582
309,patient wa enrolled,6.320739834081327
310,related cost,6.313429533429533
311,share,6.310504497390827
312,employee,6.308077150061699
313,effective date,6.305059989567032
314,development expense,6.2946533738062715
315,lease agreement,6.290034109012011
316,time,6.28617816091954
317,agreement,6.280345659163987
318,single study,6.273920005823051
319,recurring measurement,6.265464743589744
320,exercise date,6.265118850193477
321,restricted cash,6.262091503267974
322,based therapy,6.244897959183673
323,related expense,6.244804964539007
324,advance payment,6.2353896103896105
325,based award,6.230233815380457
326,expense,6.2247516571786115
327,sum,6.216666666666667
328,remaining warrant,6.213636231895514
329,milestone payment,6.200009531071292
330,national institute,6.193642674461088
331,price,6.185757575757576
332,year,6.163556843228857
333,government contract,6.16023212563714
334,maturity date,6.154074074074074
335,capital resource,6.148659003831417
336,june,6.1471270664819055
337,collaboration licensing,6.134998698933126
338,marketing approval,6.129047619047618
339,company,6.125554221688676
340,clinical evidence,6.115079365079366
341,employee stock option,6.113345487015403
342,contract research,6.1093307969954145
343,term loan,6.105830830380748
344,additional fund,6.1032067731232535
345,million wa due,6.092986011127109
346,warrant wa determined,6.078772199315493
347,exercised option,6.075224365769204
348,derivative liability,6.073037817277449
349,source,6.071100917431193
350,plazomicin management belief,6.063420348058902
351,securities exchange act,6.063078216989067
352,receivable relate,6.059757236227824
353,purpose discovery platform,6.057513914656772
354,indirect research,6.050529126940549
355,service,6.040381302849984
356,barda contract,6.03526395173454
357,gates investment,6.031363620318402
358,equity award,6.025
359,option,6.009855811914009
360,funding support,6.000741918388977
361,sale security,5.995238095238095
362,plazomicin,5.993975903614458
363,issuance date disclosures,5.980246913580247
364,company,5.978887555022009
365,time improvement allowance,5.975833333333333
366,capital subject,5.965925417972832
367,research program,5.961020520887116
368,activity employee,5.956554878048781
369,share,5.9408503857461685
370,approximately wa recorded,5.939503538197391
371,discovery research,5.932391203953897
372,facility lease,5.928911138923654
373,monoclonal antibody,5.923809523809524
374,contract research,5.910918098582717
375,efficacy endpoint,5.904761904761905
376,contract funding option,5.899199728479306
377,management,5.884600614439324
378,month,5.874236874236875
379,company,5.872504576298605
380,sales agreement,5.852788840982169
381,asset liability revenue,5.843329267190747
382,period,5.836957813428402
383,month,5.8321678321678325
384,development cost,5.828981306153618
385,year contingent,5.819623187750209
386,year beginning,5.81697066785631
387,financial asset,5.812184006266468
388,patient enrollment,5.7716701902748415
389,loan agreement,5.765460304134401
390,agreement government contracts,5.764923581241909
391,million option,5.763801980545396
392,month,5.7636967349197565
393,government contract concentration,5.74110644257703
394,million payment,5.728209109730849
395,party collaboration funding,5.728099528099528
396,private placement,5.703933747412009
397,effective april,5.700729505236548
398,company,5.700105262046167
399,oral treatment,5.698332854268468
400,derivative liability,5.69820788530466
401,securities purchase agreement,5.687600188678891
402,rsus,5.685417609666818
403,million primarily due,5.68362928598091
404,default interest rate,5.668760611205434
405,development service,5.6578641207194
406,outstanding warrant,5.639872276552611
407,year service period,5.638338436385203
408,subsequent option,5.622316049038082
409,placement june,5.612658356136618
410,based option,5.611918579013282
411,total revenue,5.604979360165119
412,performance obligation,5.578609986504723
413,year research term,5.547581745379841
414,type number cost,5.5280423280423285
415,equity incentive plan,5.516181657848325
416,barda contract research,5.515313702978321
417,warrant wa recorded,5.494502536394144
418,epic,5.471726190476191
419,share,5.467277447056951
420,company,5.465729660285167
421,based target,5.462480376766091
422,term loan,5.4491805840753305
423,equity,5.443426501035197
424,treatment option,5.43443219984623
425,judgment assumption,5.427773046625505
426,company term loan,5.415194575878948
427,expense,5.409277753654654
428,oral antibiotic,5.404761904761905
429,life assumption,5.391608391608392
430,ha recognized million,5.375413533834586
431,infectious diseases,5.368421052631579
432,million including million,5.344099378881988
433,thermo fisher,5.333333333333333
434,lapse unexercised,5.314285714285715
435,approval change,5.303065693430657
436,company,5.280792316926771
437,trial,5.278713768115942
438,epic trial,5.271273291925466
439,balance sheet,5.26984126984127
440,share price change,5.254422463548757
441,june,5.252823987606597
442,april warrant liability,5.193123006026232
443,standard event,5.19147485080989
444,effective january,5.1767261967171105
445,september barda,5.166689704425553
446,prepaid expense,5.140941328175371
447,gross proceeds,5.1
448,stock options,5.095725466586393
449,care trial,5.094685990338164
450,plazomicin nda,5.08808021200448
451,net proceeds,5.076388888888889
452,office laboratory,5.057017543859649
453,advanced funds,5.056795131845842
454,consolidated subsidiary,5.056547619047619
455,drug administration,5.055555555555555
456,research program,5.047144922800992
457,average price,5.027511961722488
458,safety concern,5.024828113063407
459,consolidated statement,5.003962167689162
460,million grant,4.990536046820963
461,substantial doubt,4.9855072463768115
462,million share,4.968407911067546
463,debt instrument,4.964705882352941
464,income net,4.961004273504273
465,cash,4.94727668845316
466,issuance cost,4.925749559082892
467,cash flow,4.91764705882353
468,net cash,4.8940359477124185
469,cash,4.884898520811834
470,phase study,4.880428403755868
471,wa terminated,4.879751461988304
472,payment,4.875
473,laboratory supply,4.873684210526315
474,epic study,4.872987927565392
475,charged directly,4.872844827586206
476,funding,4.866339066339066
477,development expenses,4.862675125561723
478,operating expense,4.86063829787234
479,warrants,4.841509433962264
480,global access,4.836538461538462
481,generated solely,4.833333333333334
482,warrant,4.815494304843057
483,wa provided,4.810108604845447
484,collectability presentation,4.807142857142857
485,development authority,4.791824923132573
486,advance funds,4.764778325123153
487,antibody platform,4.763636363636364
488,supportive data,4.763513513513514
489,meaningful data,4.763513513513514
490,cash flows,4.762091503267975
491,clinical trial,4.7613526570048315
492,broad enrollment,4.75
493,corporate headquarters,4.75
494,funding pursuant,4.740202702702703
495,operating activity,4.737804878048781
496,net loss,4.734283625730994
497,monoclonal antibody,4.733333333333333
498,funding ha,4.729369369369369
499,bloodstream infection,4.729166666666667
500,care study,4.69640062597809
501,work plans,4.6952380952380945
502,cash,4.69264705882353
503,tenant improvement,4.6875
504,work,4.6869565217391305
505,biodefense pathogen,4.684210526315789
506,call options,4.681818181818182
507,equipment net,4.681652046783626
508,drug discovery,4.678004535147393
509,common stock,4.677976548837476
510,deferred revenue,4.670518207282913
511,commercial manufacturing,4.666666666666667
512,financial statement,4.663592410514768
513,compensation committee,4.655172413793103
514,additional funding,4.655161719096146
515,financing activity,4.654471544715447
516,substantial portion,4.6521739130434785
517,operating lease,4.6436170212765955
518,closed enrollment,4.642857142857142
519,data,4.64254577157803
520,remain outstanding,4.6415094339622645
521,include direct,4.629032258064516
522,medical meeting,4.625
523,deferred taxes,4.619047619047619
524,registration statement,4.608128834355828
525,mutually agreed,4.60790273556231
526,option,4.590947636209455
527,aggregate amount,4.576923076923077
528,success fee,4.575027382256298
529,stock price,4.572998193859121
530,provide important,4.571428571428571
531,gates investment,4.56945885841364
532,funding,4.569369369369369
533,quoted price,4.559090909090909
534,wa estimated,4.558077150061699
535,gates foundation,4.557634827810267
536,related expense,4.557304964539007
537,united states,4.555555555555555
538,current intention,4.555555555555555
539,drug compound,4.555555555555555
540,advance payment,4.553571428571429
541,funding source,4.552702702702703
542,revenue,4.5514705882352935
543,national institute,4.546583850931677
544,funding,4.545559845559845
545,effective january,4.543400599130663
546,capital,4.538201487491548
547,regulatory approval,4.529230769230769
548,deferred research,4.5257640369580665
549,clinical candidate,4.525593008739076
550,current liability,4.5140809011776755
551,financial information,4.509410944579994
552,award,4.508196721311475
553,market exclusivity,4.506122448979593
554,cash,4.50514705882353
555,administrative expense,4.504577691811734
556,costs,4.5
557,crystal,4.5
558,partially offset,4.5
559,wa paid,4.495822890559733
560,fee equal,4.495481927710843
561,development,4.490880253766852
562,customers,4.485714285714286
563,cash,4.484313725490196
564,revenue,4.478137254901961
565,headcount,4.4730983302411875
566,period,4.466503267973856
567,government funding,4.463416988416988
568,additional expense,4.463097314265783
569,infection,4.4625
570,funds,4.461206896551724
571,infection,4.459663120567376
572,basis,4.457142857142857
573,amount,4.451923076923077
574,rent abatement,4.45
575,closely related,4.446666666666667
576,teaes,4.446666666666667
577,comprehensive loss,4.443609022556391
578,interest income,4.437246963562753
579,regulatory filing,4.435897435897436
580,inducement material,4.434782608695652
581,financial instruments,4.430463576158941
582,financial institution,4.430463576158941
583,market offering,4.429410120212468
584,colistin therapy,4.428571428571429
585,ha determined,4.426666666666667
586,key assumption,4.420454545454545
587,morbidity,4.420289855072464
588,factor,4.420289855072464
589,public including,4.420289855072464
590,policy election,4.417582417582418
591,stock appreciation,4.413907284768212
592,profit foundation,4.408950617283951
593,exclusive license,4.407407407407407
594,requires urgent,4.404761904761905
595,related cost,4.404338624338624
596,cost,4.404338624338624
597,negative impact,4.404324324324325
598,antibody,4.4
599,superiority,4.4
600,cancelable agreement,4.396417087735416
601,expansion option,4.393882646691636
602,current asset,4.388888888888888
603,credit,4.380788177339902
604,active market,4.380196523053666
605,total funding,4.36936936936937
606,decision,4.363636363636363
607,platform technology,4.363636363636363
608,stock option,4.363345487015403
609,clinical study,4.363067292644757
610,preclinical study,4.359595070422535
611,liability assets,4.35852534562212
612,inducement plan,4.3545356951154055
613,regulatory review,4.352564102564102
614,administrative cost,4.351611351611352
615,transition method,4.35
616,foreseeable future,4.343859649122807
617,aminoglycoside product,4.341397849462366
618,related service,4.3398705501618124
619,stock plan,4.333660371187965
620,commercial production,4.333333333333334
621,composite endpoint,4.333333333333334
622,microbiological eradication,4.333333333333334
623,allotment option,4.324438202247191
624,revenue,4.318137254901961
625,entirety,4.316326530612245
626,contractual obligation,4.315789473684211
627,adjustment,4.3125
628,adjustment,4.3125
629,customary affirmative,4.3125
630,product candidate,4.3114353026458865
631,directly observed,4.310344827586206
632,directly identifiable,4.310344827586206
633,advantageous market,4.3061224489795915
634,market participant,4.3061224489795915
635,adequate funding,4.302702702702703
636,manufacturing agreement,4.301178992497321
637,credit loss,4.295825771324864
638,development organization,4.294982817869416
639,market activity,4.293927327028372
640,collectability,4.285714285714286
641,nightmare bacteria,4.285714285714286
642,commercial launch,4.283333333333333
643,milestone payment,4.281976744186046
644,decision,4.281669150521609
645,debt security,4.2785714285714285
646,clinical development,4.277205040091638
647,preclinical development,4.273732817869416
648,ionis pharmaceuticals,4.272727272727273
649,compensated ionis,4.272727272727273
650,lease payment,4.2686170212765955
651,commercial validation,4.266666666666667
652,outstanding rsus,4.2665094339622645
653,share data,4.265779374540704
654,barda funding,4.264241164241164
655,solar capital,4.262800417972832
656,national institutes,4.260869565217391
657,wa,4.259559154295997
658,interim period,4.258169934640523
659,expense,4.257304964539006
660,unvested share,4.25226586102719
661,annual report,4.251672240802676
662,operation,4.24841088227816
663,performance conditions,4.246153846153846
664,private placement,4.242028985507247
665,obtaining fda,4.241666666666667
666,derivative liability,4.236303123399898
667,related disclosure,4.236140350877193
668,expense,4.233925969105217
669,obligation,4.22883295194508
670,preclinical program,4.227599557522124
671,additional allowance,4.227459016393443
672,item management,4.225
673,commercial assay,4.222222222222222
674,clinical cure,4.222222222222222
675,primarily due,4.221724524076148
676,research funding,4.20941912061315
677,contract,4.202614379084967
678,debt instruments,4.2
679,debt host,4.2
680,debt discount,4.2
681,crystal biosciences,4.1875
682,work plan,4.18641975308642
683,clinical cost,4.17989417989418
684,information item,4.178947368421053
685,funding,4.177702702702703
686,discovery development,4.177431797461253
687,share,4.172555716099654
688,wa derived,4.167251461988304
689,interim reporting,4.166666666666666
690,development expense,4.1656211157417555
691,interest expense,4.163269876819709
692,plan,4.162610229276896
693,exchange price,4.159090909090909
694,exit price,4.159090909090909
695,primarily accessed,4.157894736842105
696,financial condition,4.1551012573183606
697,interest rate,4.152631578947369
698,sales agreement,4.149663840982169
699,warrant,4.147884373690825
700,warrant,4.147884373690825
701,existing contract,4.147058823529411
702,antibacterial drug,4.146464646464646
703,allocated indirect,4.143812709030101
704,recently announced,4.142857142857142
705,additional disclosure,4.141932700603969
706,ongoing study,4.140845070422535
707,credit risk,4.137931034482758
708,credit,4.137931034482758
709,option,4.136938202247191
710,net settlement,4.136388888888889
711,initially capitalized,4.133333333333334
712,security interest,4.131203007518797
713,facility lease,4.128911138923654
714,operation,4.127826086956522
715,fiscal year,4.127315495442517
716,share equal,4.12726586102719
717,working capital,4.126436781609195
718,capital resources,4.126436781609195
719,hovione depending,4.125
720,hovione,4.125
721,front fee,4.120481927710843
722,final fee,4.120481927710843
723,professional fee,4.120481927710843
724,operation,4.118659420289855
725,initial term,4.112234042553192
726,substantial completion,4.106719367588933
727,limited activity,4.10545193687231
728,additional share,4.104724877420633
729,cost,4.104338624338624
730,equity security,4.103571428571429
731,future period,4.10202958376333
732,operation,4.101449275362318
733,prospectus,4.1
734,discount rate,4.1
735,lower rate,4.1
736,exchange act,4.097560975609756
737,act,4.097560975609756
738,innovation act,4.097560975609756
739,approval,4.093333333333334
740,period,4.091503267973856
741,comparable period,4.091503267973856
742,cure period,4.091503267973856
743,significant judgments,4.088235294117647
744,material impact,4.08
745,historical information,4.078947368421053
746,marketable security,4.078571428571429
747,similar security,4.078571428571429
748,treasury security,4.078571428571429
749,amount,4.076923076923077
750,cre infection,4.075833333333334
751,negative covenant,4.074324324324325
752,charitable default,4.071684587813619
753,disease,4.066666666666666
754,development program,4.06383237539154
755,immediately due,4.0638297872340425
756,pneumonia,4.0638297872340425
757,securities,4.063078216989067
758,remaining life,4.0606060606060606
759,company,4.060417609666818
760,principal participant,4.0576923076923075
761,development space,4.054982817869416
762,incurred research,4.053383084577114
763,revenue,4.0514705882352935
764,remaining term,4.047840103159253
765,security agreement,4.046417087735416
766,development activity,4.0427876959181965
767,dividend yield,4.041025641025641
768,providing general,4.03921568627451
769,cash charge,4.031932773109244
770,research discovery,4.029165397502284
771,million wa,4.029156223893066
772,license fee,4.027889335118251
773,funding condition,4.027340383862123
774,stockholders equity,4.025
775,mezzanine equity,4.025
776,allocated expense,4.02368177613321
777,significant concentration,4.02156862745098
778,valuation security,4.019747899159664
779,base rent,4.0181818181818185
780,common share,4.016335125096454
781,development cost,4.012654775541373
782,future award,4.010526315789473
783,remaining option,4.010044262853252
784,necessarily indicative,4.0
785,accumulated deficit,4.0
786,historical experience,4.0
787,readily apparent,4.0
788,unrealized gain,4.0
789,temporary decline,4.0
790,financially sound,4.0
791,institution,4.0
792,explicit requirement,4.0
793,factor,4.0
794,le transparency,4.0
795,intellectual property,4.0
796,voluntary prepayment,4.0
797,voluntarily prepay,4.0
798,similar expression,4.0
799,risk factors,4.0
800,sample size,4.0
801,varying degree,4.0
802,human services,4.0
803,medicine,4.0
804,multifaceted approach,4.0
805,wellcome trust,4.0
806,higher collection,4.0
807,property plant,4.0
808,competing technology,4.0
809,practical expedients,4.0
810,actively traded,4.0
811,tenant improvements,4.0
812,infrastructure,4.0
813,strategic relationship,4.0
814,underwriting discount,4.0
815,efficacious dos,4.0
816,monte carlo,4.0
817,minimum quantity,4.0
818,cancellation clause,4.0
819,unused portion,4.0
820,freely tradable,4.0
821,freely tradeable,4.0
822,microbiologically evaluable,4.0
823,enzyme essential,4.0
824,outer membrane,4.0
825,continued progress,4.0
826,operation cash,3.9988064791133846
827,company belief,3.996665332799787
828,sale security,3.9952380952380953
829,price,3.992424242424242
830,negative pledge,3.9909909909909906
831,accompanying note,3.9890710382513666
832,rsu activity,3.9878048780487805
833,activity,3.9878048780487805
834,similar term,3.9872340425531916
835,material term,3.9872340425531916
836,potential approval,3.98463768115942
837,wa recorded,3.982981799066956
838,global commercialization,3.9823717948717947
839,employee,3.980769230769231
840,sale agent,3.979166666666667
841,company,3.978887555022009
842,security deposit,3.9785714285714286
843,uncertainty,3.975845410628019
844,december,3.9750537634408603
845,development plan,3.974735904289169
846,interest,3.970664365832614
847,collaborative agreement,3.967845659163987
848,expense relate,3.9677811550151976
849,facility amortization,3.9660633484162897
850,black scholes,3.962962962962963
851,research development,3.9616992357798635
852,ipo net,3.9610042735042734
853,approval,3.96
854,accrued liability,3.95852534562212
855,cost extension,3.9576719576719577
856,cost,3.9576719576719577
857,industry model,3.9565217391304346
858,simulation model,3.9565217391304346
859,calibration model,3.9565217391304346
860,crystal,3.9561170212765955
861,consulting fee,3.953815261044177
862,exercise price,3.950135685210312
863,contract funding,3.9497615262321144
864,option,3.949438202247191
865,estimated cost,3.948497645745352
866,validation program,3.942182890855457
867,warrant ha,3.9381874039938554
868,lender,3.9375
869,loss,3.935672514619883
870,asu introduces,3.935483870967742
871,asu simplifies,3.935483870967742
872,actual timing,3.928571428571429
873,data input,3.928147659854977
874,million committed,3.9274220032840725
875,rendered provided,3.9246753246753245
876,part,3.9243943191311614
877,future research,3.917242733699921
878,research program,3.915565975432571
879,share,3.915056558701609
880,liability,3.9150470847525547
881,plazomicin,3.9142657586869216
882,purchase price,3.9133281972265026
883,million related,3.9085714285714284
884,strategic milestone,3.9069767441860463
885,research institution,3.906716417910448
886,research team,3.906716417910448
887,fda general,3.9058823529411764
888,quarterly report,3.9038461538461537
889,ourannual report,3.9038461538461537
890,disease control,3.9
891,financial resource,3.8971302428256074
892,research activity,3.894521295959228
893,antibacterial candidate,3.894279877425945
894,lease,3.8936170212765955
895,continued service,3.8932038834951457
896,subsequent year,3.8917265230114393
897,patent claim,3.8846153846153846
898,sale agreement,3.884512325830654
899,lease term,3.8808510638297875
900,license agreement,3.8752530665713945
901,discovery effort,3.872448979591837
902,june borrowings,3.870629370629371
903,stockholder,3.8684210526315788
904,approved proceed,3.8684210526315788
905,approved commercializing,3.8684210526315788
906,approved lactam,3.8684210526315788
907,fda pre,3.8666666666666667
908,anticipated result,3.866555462885738
909,december cash,3.866034155597723
910,term loan,3.862973687523606
911,term,3.8622340425531916
912,liability page,3.8585253456221196
913,regular basis,3.857142857142857
914,amount,3.8547008547008548
915,estimated basis,3.8479685452162515
916,loan agreement,3.8435853041344012
917,thousand unaudited,3.8435374149659864
918,provide signing,3.8428571428571425
919,agreement,3.842845659163987
920,amortization expense,3.841407528641571
921,nsp,3.8375
922,increased size,3.836734693877551
923,early exercise,3.8364993215739487
924,place restriction,3.833333333333333
925,identical asset,3.833333333333333
926,similar asset,3.833333333333333
927,declared effective,3.830985915492958
928,developing country,3.8277777777777775
929,administrative support,3.8253119429590017
930,actual result,3.8211009174311927
931,fee,3.8204819277108433
932,plan page,3.819753086419753
933,input,3.819396051103368
934,categorized based,3.816326530612245
935,hovione beginning,3.814655172413793
936,additional million,3.8143637782982047
937,remaining share,3.812871921633251
938,underwriter,3.8125
939,clinical evaluation,3.810457516339869
940,government contract,3.8077731092436973
941,development effort,3.8049828178694156
942,committed fund,3.804500292226768
943,market,3.8000983525940497
944,million relates,3.795238095238095
945,potentially subject,3.794034090909091
946,subsequently exercised,3.7924528301886795
947,exercised historically,3.7924528301886795
948,level price,3.785757575757576
949,exchange commission,3.7857142857142856
950,underwriting commission,3.7857142857142856
951,prepaid expense,3.777304964539007
952,plan,3.7768959435626104
953,increase wa,3.7747986317996247
954,cost,3.7739984882842026
955,safety profile,3.7727272727272725
956,fda page,3.7666666666666666
957,funding million,3.7646074646074643
958,underwriter option,3.761938202247191
959,term,3.7599613152804645
960,acceptable term,3.7599613152804645
961,account payable,3.7598039215686274
962,discount,3.7542372881355934
963,barda,3.7539912917271407
964,patient,3.753488372093023
965,plan,3.753086419753086
966,share,3.7522658610271904
967,company,3.7522208883553425
968,effort,3.75
969,employee,3.75
970,landlord disburses,3.75
971,year period,3.7451345528900575
972,funded primarily,3.7441016333938295
973,measurement,3.7435897435897436
974,increased research,3.7434511117879987
975,option,3.7418910324358703
976,defense,3.741071428571429
977,full utilization,3.7407407407407405
978,full term,3.7279747832939325
979,letter agreement,3.725421416739745
980,customary event,3.7242647058823533
981,estimate including,3.7233201581027666
982,april covering,3.723076923076923
983,product,3.7223502304147464
984,purchase agreement,3.7220829472995804
985,judgment,3.7142857142857144
986,party,3.7142857142857144
987,date,3.712169312169312
988,product subject,3.7111895161290325
989,ongoing collaboration,3.7111111111111112
990,sale commission,3.7023809523809526
991,contract revenue,3.6985294117647056
992,revenue contract,3.6985294117647056
993,assumption page,3.6954545454545453
994,agreement,3.6951183864367145
995,company,3.6950780312124847
996,fair market,3.691890239241764
997,additional fund,3.6914420672409003
998,revenue contracts,3.68783422459893
999,commenced operation,3.681159420289855
1000,operation,3.681159420289855
1001,maturity,3.6799999999999997
1002,collaboration agreement,3.6789567702750983
1003,advance plazomicin,3.672547332185886
1004,differ materially,3.666666666666667
1005,business strategy,3.666666666666667
1006,successfully developed,3.666666666666667
1007,calendar year,3.653631284916201
1008,antibacterial agent,3.653409090909091
1009,contingent liability,3.650833037929812
1010,subsequent event,3.6498599439775914
1011,scape ha,3.648888888888889
1012,amount,3.6444906444906446
1013,safety,3.6393939393939396
1014,payments,3.6363636363636367
1015,renal function,3.6363636363636367
1016,vestibular function,3.6363636363636367
1017,company,3.6355542216886754
1018,judgment,3.63231850117096
1019,issuance,3.6294605107390496
1020,concern topic,3.628571428571429
1021,dtra,3.628484848484849
1022,lowest level,3.626666666666667
1023,threshold level,3.626666666666667
1024,management,3.625
1025,broad range,3.625
1026,fair statement,3.6188966246180003
1027,barda contract,3.608597285067873
1028,generally derived,3.6
1029,director,3.6
1030,volatility,3.5961538461538463
1031,share vest,3.5855991943605234
1032,share,3.5855991943605234
1033,expected term,3.583387888707038
1034,orderly transaction,3.583333333333333
1035,licensing arrangement,3.583056478405316
1036,operation page,3.581159420289855
1037,operations,3.575
1038,level valuation,3.567843137254902
1039,lease amendment,3.5602836879432624
1040,final settlement,3.56
1041,service,3.559870550161812
1042,august pursuant,3.5594512195121952
1043,temporary impairment,3.5555555555555554
1044,contract research,3.553775241439859
1045,research contract,3.553775241439859
1046,year page,3.553631284916201
1047,facility depreciation,3.553475935828877
1048,period,3.5530417295123176
1049,company,3.5522208883553423
1050,company,3.5522208883553423
1051,company,3.5522208883553423
1052,company,3.5522208883553423
1053,company,3.5522208883553423
1054,company,3.5522208883553423
1055,loan,3.5522102332057086
1056,guidance simplifies,3.55
1057,authoritative guidance,3.55
1058,implementation guidance,3.55
1059,contract page,3.5470588235294116
1060,applicable law,3.5454545454545454
1061,inferiority margin,3.5454545454545454
1062,inferiority,3.5454545454545454
1063,company,3.5430465764287367
1064,period,3.541503267973856
1065,closing price,3.5384012539184955
1066,operation basis,3.538302277432712
1067,full exercise,3.5317855168601437
1068,government agency,3.5291353383458643
1069,year grant,3.528631284916201
1070,amendment,3.5238095238095237
1071,million remaining,3.5225108225108226
1072,future issuance,3.5166991552956466
1073,initial fair,3.5107677902621726
1074,product,3.5080645161290325
1075,purchase share,3.506503149162784
1076,time period,3.50483660130719
1077,plazomicin program,3.5028254611365814
1078,month libor,3.5
1079,repurchase relating,3.5
1080,twelve month,3.5
1081,rapidly address,3.5
1082,closing fee,3.49979227253843
1083,produce plazomicin,3.4939759036144578
1084,permit plazomicin,3.4939759036144578
1085,plazomicin,3.4939759036144578
1086,control transaction,3.4833333333333334
1087,contract modification,3.480392156862745
1088,potential effect,3.477511244377811
1089,devoted substantially,3.473684210526316
1090,warrant liability,3.4700460829493087
1091,company review,3.468887555022009
1092,director,3.4684210526315793
1093,completed contract,3.4652406417112296
1094,issuance cost,3.4638447971781305
1095,million bringing,3.461904761904762
1096,share subject,3.4553908610271904
1097,patient,3.453488372093023
1098,patient,3.453488372093023
1099,company,3.445837909631938
1100,present intention,3.4444444444444446
1101,fully vested,3.4444444444444446
1102,plazomicin option,3.443414105861649
1103,subsequent quarter,3.4380952380952383
1104,asu clarifies,3.435483870967742
1105,borrowing rate,3.4333333333333336
1106,vest,3.4333333333333336
1107,cowen,3.430894308943089
1108,entity,3.428571428571429
1109,entity,3.428571428571429
1110,constitutes complete,3.428571428571429
1111,earlier stage,3.428571428571429
1112,size timing,3.428571428571429
1113,commercialization milestone,3.42781007751938
1114,potentially enter,3.424242424242424
1115,approximately million,3.4184265010351966
1116,thousand license,3.4176114890400604
1117,cost,3.4122174122174123
1118,potential commercialization,3.41213768115942
1119,thousand page,3.410204081632653
1120,approximately patient,3.4100101112234578
1121,company,3.409363745498199
1122,plazomicin,3.4070193818753274
1123,anticipate general,3.396358543417367
1124,full year,3.394372025656942
1125,lender,3.3936170212765955
1126,tier,3.3857677902621726
1127,company,3.3855542216886754
1128,estimated fair,3.376593478335567
1129,liability,3.3742556827007713
1130,june notes,3.370629370629371
1131,company,3.3704027065371602
1132,level measurement,3.3702564102564105
1133,share,3.367650476411806
1134,part,3.357142857142857
1135,aggressive action,3.357142857142857
1136,employee director,3.35
1137,date,3.349074074074074
1138,pay million,3.3476190476190473
1139,material change,3.343065693430657
1140,june,3.3271511097598054
1141,information,3.3231334149326806
1142,amount,3.321109123434705
1143,historical result,3.3211009174311927
1144,asset,3.3201754385964914
1145,effective date,3.305059989567032
1146,warrant,3.303973567515868
1147,director subject,3.303125
1148,warrant exercise,3.302565513446592
1149,march notes,3.302158273381295
1150,resource allocation,3.3
1151,amortized cost,3.291005291005291
1152,company,3.2794936156280694
1153,control principle,3.275
1154,applicable condition,3.270092226613966
1155,change,3.264940693430657
1156,march approximately,3.2586800125117295
1157,company,3.2445285806630344
1158,required quantity,3.244186046511628
1159,company,3.231233234034354
1160,estimate,3.221063089915549
1161,measurement date,3.2176638176638175
1162,evergreen increase,3.2075471698113205
1163,increase significantly,3.2075471698113205
1164,june,3.2073640645069217
1165,prepared assuming,3.2
1166,fourth quarter,3.2
1167,amortization,3.192673992673993
1168,developing plazomicin,3.1884203480589024
1169,maturity,3.1799999999999997
1170,performance,3.167582417582418
1171,million subject,3.165029761904762
1172,september share,3.1649642737256034
1173,contract arrangement,3.158686730506156
1174,potential commitment,3.1579710144927535
1175,operation,3.1548436308161705
1176,maturity date,3.154074074074074
1177,shares,3.1538461538461537
1178,entity condition,3.153209109730849
1179,march,3.1388929672588457
1180,purchase premium,3.1388526727509776
1181,record research,3.1374856486796787
1182,june share,3.1228952316565612
1183,valuation hierarchy,3.1135902636916835
1184,company default,3.0683499206134064
1185,march share,3.0544241344084853
1186,level input,3.04130081300813
1187,applicable plazomicin,3.039430449069003
1188,lease,3.0364741641337387
1189,million settlement,3.0219047619047616
1190,successful commercialization,3.020833333333333
1191,expected time,3.00948717948718
1192,company,2.9679512254339935
1193,lender,2.961904761904762
1194,antibacterial treatment,2.958256029684601
1195,plazomicin,2.95588066551922
1196,successful completion,2.9545454545454546
1197,concern summary,2.928571428571429
1198,company measure,2.9272208883553423
1199,company,2.9272208883553423
1200,support plazomicin,2.925348452634066
1201,million million,2.9238095238095236
1202,company fund,2.8912039392028
1203,recorded million,2.877635098983413
1204,plazomicin treatment,2.861322842389968
1205,company,2.855251191385645
1206,closing date,2.85338441890166
1207,company,2.8463385354141657
1208,company doe,2.837935174069628
1209,reasonable assurance,2.833333333333333
1210,june,2.8325341325341324
1211,thousand depreciation,2.828385899814471
1212,august subject,2.8250762195121952
1213,company,2.8214516575861115
1214,condensed,2.8076923076923075
1215,quot,2.7777777777777777
1216,march million,2.764063035286057
1217,extent,2.744186046511628
1218,anticipate intend,2.741758241758242
1219,epic,2.732142857142857
1220,june change,2.7136950640600275
1221,estimate fair,2.6887980932924753
1222,million increase,2.6694519317160825
1223,issued,2.6363636363636362
1224,money,2.625
1225,consolidation achaogen,2.571428571428571
1226,awarded,2.5636363636363635
1227,balance,2.5555555555555554
1228,retrospective,2.5555555555555554
1229,current,2.5555555555555554
1230,trial,2.5391304347826087
1231,lead,2.5384615384615383
1232,granted,2.5081967213114753
1233,aggregate,2.5
1234,proceeds,2.5
1235,discover,2.5
1236,advanced,2.4705882352941178
1237,committed,2.4655172413793105
1238,line,2.4545454545454546
1239,accounting,2.4473684210526314
1240,related,2.4466666666666668
1241,pursuant,2.4375
1242,modified,2.4193548387096775
1243,espp,2.408333333333333
1244,requires,2.4047619047619047
1245,external,2.4
1246,supply,2.4
1247,payment,2.375
1248,equal,2.375
1249,niaid,2.357142857142857
1250,additional,2.3524590163934427
1251,annual,2.347826086956522
1252,manufacturing,2.3333333333333335
1253,relates,2.3333333333333335
1254,endpoint,2.3333333333333335
1255,cash,2.3176470588235296
1256,obligation,2.3157894736842106
1257,market,2.306122448979592
1258,funding,2.3027027027027027
1259,enrolled,2.3
1260,investment,2.295774647887324
1261,nonclinical,2.2941176470588234
1262,marketing,2.2857142857142856
1263,ionis,2.272727272727273
1264,commitments,2.272727272727273
1265,received,2.2666666666666666
1266,work,2.2666666666666666
1267,source,2.25
1268,provided,2.242857142857143
1269,organization,2.24
1270,facility,2.235294117647059
1271,statement,2.233128834355828
1272,clinical,2.2222222222222223
1273,preclinical,2.21875
1274,obtain,2.2
1275,number,2.2
1276,debt,2.2
1277,rent,2.2
1278,sum,2.2
1279,advance,2.1785714285714284
1280,sold,2.1627906976744184
1281,government,2.1607142857142856
1282,price,2.159090909090909
1283,loss,2.1578947368421053
1284,primarily,2.1578947368421053
1285,incurred,2.1466666666666665
1286,provide,2.142857142857143
1287,closed,2.142857142857143
1288,study,2.140845070422535
1289,include,2.129032258064516
1290,management,2.125
1291,hovione,2.125
1292,initial,2.125
1293,offering,2.1232876712328768
1294,discovery,2.122448979591837
1295,fee,2.1204819277108435
1296,limited,2.1176470588235294
1297,expense,2.1106382978723404
1298,equipment,2.1052631578947367
1299,rate,2.1
1300,litigation,2.1
1301,approval,2.0933333333333333
1302,period,2.0915032679738563
1303,significant,2.088235294117647
1304,account,2.0833333333333335
1305,impact,2.08
1306,information,2.0789473684210527
1307,security,2.0785714285714287
1308,amount,2.076923076923077
1309,active,2.074074074074074
1310,licensing,2.0714285714285716
1311,total,2.066666666666667
1312,due,2.0638297872340425
1313,principal,2.0576923076923075
1314,development,2.0549828178694156
1315,interest,2.0526315789473686
1316,revenue,2.051470588235294
1317,early,2.0454545454545454
1318,general,2.0392156862745097
1319,equity,2.025
1320,future,2.0105263157894737
1321,program,2.0088495575221237
1322,product,2.0080645161290325
1323,efficacy,2.0
1324,requirement,2.0
1325,expenditure,2.0
1326,scope,2.0
1327,normal,2.0
1328,institution,2.0
1329,experienced,2.0
1330,exchange,2.0
1331,award,2.0
1332,observable,2.0
1333,life,2.0
1334,determined,2.0
1335,risk,2.0
1336,public,2.0
1337,material,2.0
1338,stage,2.0
1339,progress,2.0
1340,offset,2.0
1341,held,2.0
1342,property,2.0
1343,technology,2.0
1344,mmitt,2.0
1345,cohort,2.0
1346,colistin,2.0
1347,estimated,1.9908256880733946
1348,activity,1.9878048780487805
1349,term,1.9872340425531916
1350,agreement,1.9678456591639872
1351,securities,1.9655172413793103
1352,barda,1.9615384615384615
1353,liability,1.9585253456221199
1354,cost,1.9576719576719577
1355,measured,1.9565217391304348
1356,approximately,1.9565217391304348
1357,model,1.9565217391304348
1358,launch,1.95
1359,option,1.949438202247191
1360,asu,1.935483870967742
1361,concentration,1.9333333333333333
1362,validation,1.9333333333333333
1363,paid,1.9285714285714286
1364,included,1.921875
1365,plan,1.9197530864197532
1366,make,1.9180327868852458
1367,sale,1.9166666666666667
1368,allocated,1.9130434782608696
1369,includes,1.9130434782608696
1370,overhead,1.9090909090909092
1371,license,1.9074074074074074
1372,milestone,1.9069767441860466
1373,research,1.9067164179104477
1374,report,1.9038461538461537
1375,conduct,1.903225806451613
1376,page,1.9
1377,deposit,1.9
1378,lease,1.8936170212765957
1379,agreed,1.8936170212765957
1380,service,1.8932038834951457
1381,potential,1.891304347826087
1382,liquidity,1.8888888888888888
1383,assay,1.8888888888888888
1384,pay,1.8857142857142857
1385,loan,1.8757396449704142
1386,grant,1.875
1387,allowance,1.875
1388,approved,1.868421052631579
1389,standard,1.8666666666666667
1390,fda,1.8666666666666667
1391,basis,1.8571428571428572
1392,relate,1.8571428571428572
1393,adopted,1.8571428571428572
1394,expire,1.8571428571428572
1395,performance,1.8461538461538463
1396,increased,1.836734693877551
1397,asset,1.8333333333333333
1398,vest,1.8333333333333333
1399,consulting,1.8333333333333333
1400,modification,1.8333333333333333
1401,executed,1.8333333333333333
1402,effective,1.8309859154929577
1403,identified,1.8235294117647058
1404,completed,1.8181818181818181
1405,base,1.8181818181818181
1406,based,1.816326530612245
1407,underwriter,1.8125
1408,target,1.8
1409,expires,1.8
1410,assumption,1.7954545454545454
1411,exercised,1.7924528301886793
1412,exercise,1.791044776119403
1413,disclosure,1.7894736842105263
1414,commission,1.7857142857142858
1415,reported,1.7777777777777777
1416,considered,1.7777777777777777
1417,nda,1.7777777777777777
1418,safety,1.7727272727272727
1419,acceptable,1.7727272727272727
1420,day,1.7692307692307692
1421,letter,1.7575757575757576
1422,purchase,1.7542372881355932
1423,share,1.7522658610271904
1424,evidence,1.75
1425,effort,1.75
1426,covenant,1.75
1427,previously,1.75
1428,employee,1.75
1429,seek,1.75
1430,measurement,1.7435897435897436
1431,full,1.7407407407407407
1432,amortization,1.7307692307692308
1433,reached,1.7272727272727273
1434,condition,1.7246376811594204
1435,april,1.7230769230769232
1436,party,1.7142857142857142
1437,judgment,1.7142857142857142
1438,charge,1.7142857142857142
1439,intended,1.7142857142857142
1440,collaboration,1.711111111111111
1441,performed,1.7096774193548387
1442,subject,1.703125
1443,adoption,1.7
1444,signing,1.7
1445,developing,1.6944444444444444
1446,contingent,1.6923076923076923
1447,filed,1.6923076923076923
1448,beginning,1.6896551724137931
1449,consultant,1.6875
1450,rendered,1.6818181818181819
1451,operation,1.681159420289855
1452,cre,1.68
1453,maturity,1.68
1454,entered,1.6790123456790123
1455,payable,1.6764705882352942
1456,business,1.6666666666666667
1457,amendment,1.6666666666666667
1458,prepaid,1.6666666666666667
1459,health,1.6666666666666667
1460,differ,1.6666666666666667
1461,pledge,1.6666666666666667
1462,apply,1.6666666666666667
1463,developed,1.6666666666666667
1464,unmet,1.6666666666666667
1465,note,1.6557377049180328
1466,year,1.6536312849162011
1467,contract,1.6470588235294117
1468,contracts,1.6363636363636365
1469,function,1.6363636363636365
1470,made,1.6363636363636365
1471,level,1.6266666666666667
1472,rsus,1.625
1473,sell,1.6153846153846154
1474,derived,1.6
1475,director,1.6
1476,transition,1.6
1477,expected,1.5961538461538463
1478,antibacterial,1.5909090909090908
1479,evaluation,1.588235294117647
1480,effect,1.5862068965517242
1481,funded,1.5862068965517242
1482,transaction,1.5833333333333333
1483,purpose,1.5714285714285714
1484,intent,1.5714285714285714
1485,incentive,1.5714285714285714
1486,primary,1.5714285714285714
1487,election,1.5714285714285714
1488,carrying,1.5675675675675675
1489,settlement,1.56
1490,uncertainty,1.5555555555555556
1491,impairment,1.5555555555555556
1492,company,1.552220888355342
1493,guidance,1.55
1494,december,1.5483870967741935
1495,applicable,1.5454545454545454
1496,inferiority,1.5454545454545454
1497,capitalized,1.5333333333333334
1498,commercialization,1.5208333333333333
1499,default,1.5161290322580645
1500,arrangement,1.5116279069767442
1501,warrant,1.5115207373271888
1502,thousand,1.510204081632653
1503,issuance,1.5061728395061729
1504,assurance,1.5
1505,reflect,1.5
1506,month,1.5
1507,greater,1.5
1508,lender,1.5
1509,repurchase,1.5
1510,extent,1.5
1511,summary,1.5
1512,successful,1.5
1513,commercialized,1.5
1514,clarifies,1.5
1515,address,1.5
1516,plazomicin,1.4939759036144578
1517,recognized,1.486842105263158
1518,date,1.474074074074074
1519,substantially,1.4736842105263157
1520,resource,1.4666666666666666
1521,million,1.4619047619047618
1522,resulted,1.4615384615384615
1523,completion,1.4545454545454546
1524,involved,1.4545454545454546
1525,patient,1.4534883720930232
1526,presented,1.45
1527,return,1.4444444444444444
1528,present,1.4444444444444444
1529,treat,1.4444444444444444
1530,fully,1.4444444444444444
1531,exercisable,1.434782608695652
1532,support,1.4313725490196079
1533,concern,1.4285714285714286
1534,entity,1.4285714285714286
1535,timing,1.4285714285714286
1536,defense,1.4285714285714286
1537,earlier,1.4285714285714286
1538,complete,1.4285714285714286
1539,identifying,1.4166666666666667
1540,recorded,1.4157303370786516
1541,input,1.4146341463414633
1542,time,1.4133333333333333
1543,september,1.4126984126984128
1544,event,1.411764705882353
1545,january,1.4102564102564104
1546,nsp,1.4
1547,fair,1.3857677902621723
1548,ipo,1.3846153846153846
1549,claim,1.3846153846153846
1550,intend,1.3846153846153846
1551,premium,1.3846153846153846
1552,closing,1.3793103448275863
1553,principle,1.375
1554,measure,1.375
1555,range,1.375
1556,elect,1.375
1557,june,1.3706293706293706
1558,type,1.3703703703703705
1559,agency,1.368421052631579
1560,treatment,1.3673469387755102
1561,decrease,1.3636363636363635
1562,part,1.3571428571428572
1563,anticipate,1.3571428571428572
1564,action,1.3571428571428572
1565,gaap,1.3548387096774193
1566,change,1.3430656934306568
1567,fund,1.3389830508474576
1568,consolidation,1.3333333333333333
1569,cowen,1.3333333333333333
1570,reasonable,1.3333333333333333
1571,fixed,1.3333333333333333
1572,reflects,1.3333333333333333
1573,dilutive,1.3333333333333333
1574,amortized,1.3333333333333333
1575,borrowing,1.3333333333333333
1576,enter,1.3333333333333333
1577,lpxc,1.3333333333333333
1578,assessing,1.3214285714285714
1579,result,1.3211009174311927
1580,depreciation,1.3181818181818181
1581,yield,1.3076923076923077
1582,estimate,1.303030303030303
1583,march,1.3021582733812949
1584,ass,1.2941176470588236
1585,cuti,1.2857142857142858
1586,doe,1.2857142857142858
1587,classified,1.2692307692307692
1588,commitment,1.2666666666666666
1589,assessment,1.25
1590,meropenem,1.25
1591,supersede,1.25
1592,end,1.25
1593,required,1.244186046511628
1594,achaogen,1.2380952380952381
1595,record,1.2307692307692308
1596,scape,1.2222222222222223
1597,espp,1.2083333333333333
1598,increase,1.2075471698113207
1599,operations,1.2
1600,presentation,1.2
1601,prepared,1.2
1602,july,1.2
1603,amended,1.2
1604,quarter,1.2
1605,develop,1.1904761904761905
1606,dtra,1.1818181818181819
1607,hierarchy,1.1724137931034482
1608,earnings,1.1666666666666667
1609,represent,1.1666666666666667
1610,shares,1.1538461538461537
1611,set,1.1428571428571428
1612,continue,1.131578947368421
1613,case,1.125
1614,personnel,1.125
1615,august,1.1219512195121952
1616,customer,1.0909090909090908
1617,results,1.0833333333333333
1618,deducting,1.0571428571428572
1619,evaluate,1.0476190476190477
1620,serve,1.0
1621,addition,1.0
1622,completing,1.0
1623,delaware,1.0
1624,accordance,1.0
1625,sec,1.0
1626,permitted,1.0
1627,rule,1.0
1628,footnote,1.0
1629,omitted,1.0
1630,opinion,1.0
1631,eliminated,1.0
1632,read,1.0
1633,conjunction,1.0
1634,form,1.0
1635,unit,1.0
1636,connection,1.0
1637,converted,1.0
1638,inception,1.0
1639,sufficient,1.0
1640,evaluating,1.0
1641,raising,1.0
1642,unable,1.0
1643,meet,1.0
1644,forced,1.0
1645,delay,1.0
1646,reduce,1.0
1647,limit,1.0
1648,cease,1.0
1649,lack,1.0
1650,resultant,1.0
1651,order,1.0
1652,ability,1.0
1653,contemplates,1.0
1654,realization,1.0
1655,recoverability,1.0
1656,reclassification,1.0
1657,estimates,1.0
1658,preparation,1.0
1659,conformity,1.0
1660,affect,1.0
1661,believed,1.0
1662,circumstance,1.0
1663,carried,1.0
1664,acquisition,1.0
1665,excluded,1.0
1666,component,1.0
1667,accretion,1.0
1668,consists,1.0
1669,collateral,1.0
1670,enterprise,1.0
1671,deposited,1.0
1672,checking,1.0
1673,respect,1.0
1674,issuer,1.0
1675,exposed,1.0
1676,issuing,1.0
1677,delivered,1.0
1678,assured,1.0
1679,deemed,1.0
1680,reduction,1.0
1681,refundable,1.0
1682,expensed,1.0
1683,payroll,1.0
1684,utility,1.0
1685,behalf,1.0
1686,expended,1.0
1687,adjust,1.0
1688,accrual,1.0
1689,receipt,1.0
1690,good,1.0
1691,depict,1.0
1692,transfer,1.0
1693,consideration,1.0
1694,entitled,1.0
1695,fulfill,1.0
1696,uncertainties,1.0
1697,november,1.0
1698,require,1.0
1699,noncurrent,1.0
1700,february,1.0
1701,leases,1.0
1702,lessee,1.0
1703,recognize,1.0
1704,derivatives,1.0
1705,accelerate,1.0
1706,update,1.0
1707,applied,1.0
1708,classification,1.0
1709,forfeiture,1.0
1710,occur,1.0
1711,computed,1.0
1712,dividing,1.0
1713,calculation,1.0
1714,computation,1.0
1715,listed,1.0
1716,defined,1.0
1717,corroborated,1.0
1718,supported,1.0
1719,significance,1.0
1720,recovery,1.0
1721,recover,1.0
1722,food,1.0
1723,obtained,1.0
1724,probability,1.0
1725,sensitive,1.0
1726,series,1.0
1727,percentage,1.0
1728,sublicensees,1.0
1729,achievement,1.0
1730,countermeasure,1.0
1731,biothreats,1.0
1732,division,1.0
1733,department,1.0
1734,convenience,1.0
1735,termination,1.0
1736,allergy,1.0
1737,annum,1.0
1738,occurrence,1.0
1739,declare,1.0
1740,obligated,1.0
1741,earliest,1.0
1742,acceleration,1.0
1743,entitle,1.0
1744,indebtedness,1.0
1745,representing,1.0
1746,accretes,1.0
1747,issue,1.0
1748,board,1.0
1749,provision,1.0
1750,vesting,1.0
1751,designed,1.0
1752,comply,1.0
1753,nasdaq,1.0
1754,person,1.0
1755,employment,1.0
1756,individual,1.0
1757,entering,1.0
1758,authorized,1.0
1759,resulting,1.0
1760,granting,1.0
1761,discretion,1.0
1762,continues,1.0
1763,govern,1.0
1764,transferred,1.0
1765,forfeited,1.0
1766,employees,1.0
1767,output,1.0
1768,obligates,1.0
1769,reservation,1.0
1770,procurement,1.0
1771,recoverable,1.0
1772,discussion,1.0
1773,analysis,1.0
1774,forward,1.0
1775,meaning,1.0
1776,section,1.0
1777,word,1.0
1778,expect,1.0
1779,variation,1.0
1780,view,1.0
1781,point,1.0
1782,rely,1.0
1783,overview,1.0
1784,centers,1.0
1785,submit,1.0
1786,half,1.0
1787,enroll,1.0
1788,dosing,1.0
1789,inform,1.0
1790,focused,1.0
1791,mechanism,1.0
1792,taking,1.0
1793,identify,1.0
1794,goal,1.0
1795,file,1.0
1796,investigational,1.0
1797,financed,1.0
1798,nih,1.0
1799,pipeline,1.0
1800,profitable,1.0
1801,commencement,1.0
1802,prepare,1.0
1803,failure,1.0
1804,needed,1.0
1805,pursue,1.0
1806,inclusion,1.0
1807,derive,1.0
1808,commercialize,1.0
1809,extend,1.0
1810,acquiring,1.0
1811,maintenance,1.0
1812,duration,1.0
1813,attributable,1.0
1814,table,1.0
1815,preparing,1.0
1816,excess,1.0
1817,facilitate,1.0
1818,enable,1.0
1819,favor,1.0
1820,request,1.0
1821,depend,1.0
1822,decide,1.0
1823,pursuing,1.0
1824,choose,1.0
1825,seeking,1.0
1826,enforcing,1.0
1827,emergence,1.0
1828,devote,1.0
1829,remeasurement,1.0
1830,defers,1.0
1831,asus,1.0
1832,selected,1.0
1833,holder,1.0
1834,settle,1.0
1835,collaborate,1.0
1836,brings,1.0
1837,close,1.0
1838,multiple,1.0
1839,submission,1.0
1840,discussed,1.0
1841,occurred,1.0
1842,revaluation,1.0
1843,noted,1.0
1844,construction,1.0
1845,calculated,1.0
1846,withdrawal,1.0
1847,scale,1.0
1848,accessible,1.0
1849,reconciliation,1.0
1850,adopt,1.0
1851,remainder,1.0
1852,adopting,1.0
1853,safe,1.0
1854,resignation,1.0
1855,validate,1.0
1856,manufacture,1.0
1857,delivery,1.0
1858,carry,1.0
1859,chooses,1.0
1860,cancel,1.0
1861,procure,1.0
1862,expired,1.0
1863,premises,1.0
1864,replenished,1.0
1865,sooner,1.0
1866,terminate,1.0
1867,trigger,1.0
1868,redemption,1.0
1869,resale,1.0
1870,researching,1.0
1871,antibiotics,1.0
1872,exceeded,1.0
1873,objective,1.0
1874,test,1.0
1875,ema,1.0
1876,tolerated,1.0
1877,mortality,1.0
1878,orally,1.0
1879,combination,1.0
1880,begin,1.0
1881,initiate,1.0
1882,suitable,1.0
1883,synthesis,1.0
1884,ready,1.0
1885,built,1.0
1886,utilize,1.0
1887,attributed,1.0
1888,move,1.0
1889,advancement,1.0
1890,probable,1.0
1891,cochlear,1.0
